BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study
| Autor: | Pierre Nouyrigat, Louis-Marie Dourthe, Hélène Albrand, Frédéric Maloisel, Nadia Ali Amar, Jean-Luc Labourey, Nacera Sakek, Miguel Carreiro, Elisabeth Luporsi, Vincent Boulanger, Bérengère Narciso, Mauricette Michallet, Daniel Lepille, Jean-Loup Mouysset, Sophie Nahon, Pierre Soubeyran, Raouf Radji |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Pathology Cancer Research Anemia medicine.medical_treatment MEDLINE Anaemia ESA Surgical oncology Internal medicine medicine Genetics Humans Chemotherapy Longitudinal Studies Biosimilar Pharmaceuticals Erythropoietin Aged Hematology business.industry Epoetin Biosimilar Middle Aged medicine.disease Recombinant Proteins Clinical trial Oncology Hematologic Neoplasms Observational study Female France business Research Article |
| Zdroj: | BMC Cancer |
| ISSN: | 1471-2407 |
| Popis: | Background The approval of epoetin biosimilars in the European Union requires extensive scientific evaluation and stringent regulatory procedures, including post-marketing studies. The ORHEO (place of biOsimilaRs in the therapeutic management of anaemia secondary to chemotherapy in HaEmatology and Oncology) study was an observational, longitudinal, multicentre study performed in France to evaluate the efficacy and safety of biosimilar epoetins for the treatment of chemotherapy-induced anaemia (CIA) in the clinical setting. Methods Patients >18 years with CIA (haemoglobin [Hb] 18 years (mean age 66.5 years) with CIA (haemoglobin [Hb] |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|